1. Advancing Patient Care in RA

3. Introduction

4. Pathogenic Pathways in RA

5. Approved and Emerging Biological Therapies

6. Pleiotropic Biological Effects of TNF and IL-6

7. Unmet Needs in RA

8. Pleiotropic Effects of IL-6 in RA

9. IL-6 Signaling Pathway: Classic Signaling

10. IL-6 Signaling Pathway: Levels of Inhibition

11. IL-6 Signaling Pathway: Trans Signaling

12. Clinical Signature of IL-6

13. Agents Targeting the IL-6 Signaling Pathway

14. Tocilizumab: ADACTA

15. Sarilumab: MOBILITY and TARGET

16. Sarilumab: MONARCH

17. Sirukumab Trial Program

18. Sirukumab: SIRROUND-T

19. Sirukumab: SIRROUND-LTE

20. Sirukumab: SIRROUND-D

21. Sirukumab: SIRROUND-H

22. Safety Profile of Anti-IL-6 Biologics

23. Biomarkers of Joint Damage: Effect of New Anti-IL-6 Biologics

24. CVD Risk in RA

25. CVD Risk in RA: Tocilizumab

26. PROs and Depression

27. Potential Differences Between IL-6 Inhibitors: MOA

28. Concluding Remarks

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)